Purchase this article with an account.
Toshiaki Abe, Aya Katsuyama, Hideyuki Onami, Toru Nakazawa, Nobuhiro Nagai; Ranibizumab Delivery Device Using Polyethyleneglycol Dimethacrylates. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4146.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To test the extended release of ranibizumab using a polymeric system made of photopolymeized poly(ethyleneglycol) dimethacrylates.
The device consists of a reservoir, controlled-release cover, and drug formulation, which were made of photopolymeized triethyleneglycol dimethacrylate (TEGDM) and polyethyleneglycol dimethacrylate (PEGDM). Ranibizumab (10 mg/ml) was mixed with PEGDM prepolymer at the ratio of 4 to 1 (volume), and the mixture (12.5 μl) was loaded in a TEGDM reservoir (12 mm × 4.4 mm × 1.2 mm), then photopolymerized for 40 seconds with UV light. After loading the ranibizumab, a prepolymer mixture of 20% PEGDM in water was applied to the reservoir, and a glass slide was placed on the prepolymer mixture, followed by UV curing for 4 min to provide a reservoir cover. The device was incubated in 1 ml of phosphate-buffered saline (PBS) at 370C. The released ranibizumab in the collected PBS was seperated by electrophoresis and the release amount was estimated from the band intensity using a standard curve. To study the bioactivity of release ranibizumab, endothelial tube formation was assessed using anti-CD31 immunostaining.
In vitro release results show the extended release of ranibizumab from the device over 150 days. The release rate estimated from the gradient curve was 0.245 ng per day. The capiliary formation was inhibited by the medium including ranibizumab released from the device, compared with the medium including PBS released from a PBS-loaded device or non-treated medium. The results indicate that ranibizumab retained its activity when released from the device.
We established a sustained ranibizumab release device by using a photocurable polymers. The device may be promissing for ocular drug delivery system for the treatment of age-related macular disease.
This PDF is available to Subscribers Only